Faculty of Pharmacy, Université Laval, Quebec City, Quebec, Canada.
Population Health and Optimal Health Practices Research Unit, CHU de Québec - Université Laval Research Centre, Quebec City, Quebec, Canada.
Subst Use Misuse. 2022;57(10):1633-1641. doi: 10.1080/10826084.2022.2102193. Epub 2022 Jul 22.
As medical cannabis use increases in North America, establishing its safety profile is a priority. The objective of this study was to assess rates of emergency department (ED) visits and hospitalizations due to poisoning by cannabis, and cannabis-related mental health disorders among medically authorized cannabis patients in Ontario, Canada, between 2014 and 2017.
This is a retrospective cohort study of patients who received medical cannabis authorization in Ontario, Canada, using data collected in participating cannabis clinics. Outcomes included ED visit/hospitalization with a main diagnosis code for: cannabis/cannabinoid poisoning; and mental/behavioral disorders due to cannabis use. Cox proportional hazard regressions were utilized to analyze the data.
From 29,153 patients who received medical authorization, 23,091 satisfied the inclusion criteria. During a median follow-up of 240 days, 14 patients visited the ED or were hospitalized for cannabis poisoning-with an incidence rate of 8.06 per 10,000 person-years (95% CI: 4.8-13.6). A total of 26 patients visited the ED or were hospitalized for mental and behavioral disorders due to cannabis use-with an incidence rate of 15.0 per 10,000 person-years (95% CI: 10.2-22.0). Predictors of cannabis-related mental and behavioral disorders include prior substance use disorders, other mental disorders, age, diabetes, and chronic obstructive pulmonary disease.
The results suggest that the incidence of cannabis poisoning or cannabis-related mental and behavioral disorders was low among patients who were authorized to use cannabis for medical care. Identified predictors can help to target patients with potential risk of the studied outcomes.
随着医用大麻在北美的使用增加，确定其安全性至关重要。本研究旨在评估 2014 年至 2017 年期间，加拿大安大略省获得医用大麻授权的患者因大麻中毒和与大麻相关的心理健康障碍而到急诊部（ED）就诊和住院的比率。
这是一项对在加拿大安大略省获得医用大麻授权的患者进行的回顾性队列研究，使用参与的大麻诊所收集的数据。结果包括因以下主要诊断代码而导致的 ED 就诊/住院：大麻/大麻素中毒；以及因使用大麻而导致的精神/行为障碍。利用 Cox 比例风险回归分析数据。
在 29153 名获得医疗授权的患者中，有 23091 名符合纳入标准。在中位随访 240 天期间，有 14 名患者因大麻中毒到 ED 就诊或住院，发生率为 8.06/10000 人年（95%CI：4.8-13.6）。共有 26 名患者因与大麻使用相关的精神和行为障碍而到 ED 就诊或住院，发生率为 15.0/10000 人年（95%CI：10.2-22.0）。与与大麻相关的精神和行为障碍相关的预测因素包括先前的物质使用障碍、其他精神障碍、年龄、糖尿病和慢性阻塞性肺疾病。
结果表明，在获得医用大麻授权的患者中，大麻中毒或与大麻相关的精神和行为障碍的发生率较低。确定的预测因素有助于针对有研究结果潜在风险的患者。
